Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks Research

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts also recently issued reports on MNPR. HC Wainwright reiterated a “buy” rating and set a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday, June 29th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research increased their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a report on Monday, March 30th. Finally, UBS Group set a $105.00 price objective on Monopar Therapeutics in a report on Monday, June 29th. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $99.79 on Monday. The stock has a market cap of $668.59 million, a PE ratio of -52.52 and a beta of 1.46. The business’s fifty day moving average is $72.95 and its 200-day moving average is $64.26. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $112.57.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.41. Equities research analysts predict that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Sei Investments Co. grew its holdings in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after acquiring an additional 656 shares during the period. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics in the fourth quarter worth approximately $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $86,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.